Cargando…

Systemic lupus erythematosus and cardiovascular disease

Detalles Bibliográficos
Autores principales:	Ruilope, Luis M., Ruiz-Hurtado, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Invited Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803081/ https://www.ncbi.nlm.nih.gov/pubmed/33447786 http://dx.doi.org/10.1016/j.ijchy.2020.100065

Ejemplares similares

Age and blood pressure goal in women with prior coronary events
por: Ruilope, Luis M., et al.
Publicado: (2020)

Are the guidelines of the ISH devoted to a population not contemplated in the ACC/AHA guidelines?
por: Ruilope, Luis M., et al.
Publicado: (2020)

State‐of‐the‐art treatment of systemic lupus erythematosus
por: Tanaka, Yoshiya
Publicado: (2020)

Therapeutic inhibition of proteasomes in systemic lupus erythematosus
por: Hiepe, Falk, et al.
Publicado: (2011)

Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis
por: Hirose, Sachiko, et al.
Publicado: (2019)

Systemic Lupus Erythematosus and Cardiovascular Disease
por: Jha, Surajkumar B, et al.
Publicado: (2022)

Cardiovascular Disease in Systemic Lupus Erythematosus
por: McMahon, Maureen, et al.
Publicado: (2021)

Systemic lupus erythematosus and cardiovascular disease
por: Frostegård, Johan
Publicado: (2022)

SLE – Hematopoietic stem cell transplantation for systemic lupus erythematosus
por: Burt, Richard K, et al.
Publicado: (2003)

In-/off-label use of biologic therapy in systemic lupus erythematosus
por: Gatto, Mariele, et al.
Publicado: (2014)

Necrotizing fasciitis associated with systemic lupus erythematosus in a child
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2016)

Commentary: Systemic lupus erythematosus retinopathy: Eye or multisystem involvement?
por: Murugan, Sivaraman Bala, et al.
Publicado: (2023)

Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus
por: Jacobi, Annett M., et al.
Publicado: (2005)

Technology and cardiovascular diseases in the era of COVID‐19
por: Harky, Amer, et al.
Publicado: (2020)

IFN-gamma transgenic mice: clues to the pathogenesis of systemic lupus erythematosus?
por: Seery, John P
Publicado: (2000)

Cardiovascular Complications in Systemic Lupus Erythematosus
por: Alghareeb, Rahmah, et al.
Publicado: (2022)

The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus
por: Kahlenberg, J Michelle, et al.
Publicado: (2011)

Imaging Assessment of Cardiovascular Disease in Systemic Lupus Erythematosus
por: Croca, Sara C., et al.
Publicado: (2012)

Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
por: Sinicato, Nailú Angélica, et al.
Publicado: (2013)

B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2001)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
por: Stohl, William
Publicado: (2003)

SLE - Practical and theoretical barriers to the prevention of accelerated atherosclerosis in systemic lupus erythematosus
por: Costenbader, Karen H, et al.
Publicado: (2003)

Discoveries in the pathophysiology of neuropsychiatric lupus erythematosus: consequences for therapy
por: Gono, Takahisa, et al.
Publicado: (2013)

Systemic Lupus Erythematosus and Cardiovascular Diseases: A Systematic Review
por: Nor, Mohammed A, et al.
Publicado: (2023)

High Fat Diet, Metabolic Syndrome and Systemic Lupus Erythematosus: A Causal Loop
por: Perricone, Carlo, et al.
Publicado: (2020)

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2003)

Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again
por: Eisenberg, Robert
Publicado: (2006)

Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
por: Lekpa, Fernando Kemta, et al.
Publicado: (2021)

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
por: Surma, Stanisław, et al.
Publicado: (2021)

Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
por: Zeller, Carlos Borelli, et al.
Publicado: (2008)

Is colchicine the holy grail for treating inflammation and reducing cardiovascular risk?
por: Filipiak, Krzysztof J., et al.
Publicado: (2021)

Exercise training for cardiovascular patients: Push me across the threshold!
por: Ambrosetti, Marco, et al.
Publicado: (2022)

Should cerebral oximetry be used as routine monitoring for cardiovascular surgical cases?
por: Rawat, Rajinder Singh
Publicado: (2016)

Protective Effects of Probiotic Consumption in Cardiovascular Disease in Systemic Lupus Erythematosus
por: de la Visitación, Néstor, et al.
Publicado: (2019)

Elucidating the Intriguing Association Between Systemic Lupus Erythematosus and Cardiovascular Disease
por: Malik, Mushrin, et al.
Publicado: (2021)

Systemic Lupus Erythematosus and Cardiovascular Disease: A Mendelian Randomization Study
por: Gao, Ning, et al.
Publicado: (2022)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Non-traditional risk and protective factors for cardiovascular disease in systemic lupus erythematosus
por: Cederholm, A, et al.
Publicado: (2005)

The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity
por: Theofilopoulos, Argyrios N, et al.
Publicado: (2001)

Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients
por: Mercurio, Valentina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b37kln1ins0p0ji4a3grceeidn